Compare MAN & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAN | VIR |
|---|---|---|
| Founded | 1948 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 1994 | 2019 |
| Metric | MAN | VIR |
|---|---|---|
| Price | $51.73 | $9.42 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $35.67 | $19.43 |
| AVG Volume (30 Days) | 1.2M | ★ 2.4M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 4.69% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $17,957,100,000.00 | $68,556,000.00 |
| Revenue This Year | $5.12 | $270.22 |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $1,062.20 | ★ N/A |
| Revenue Growth | ★ 0.58 | N/A |
| 52 Week Low | $25.15 | $4.16 |
| 52 Week High | $55.70 | $11.66 |
| Indicator | MAN | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 75.35 | 46.94 |
| Support Level | $27.11 | $8.40 |
| Resistance Level | N/A | $10.33 |
| Average True Range (ATR) | 2.58 | 0.49 |
| MACD | 1.48 | -0.11 |
| Stochastic Oscillator | 80.35 | 21.09 |
ManpowerGroup Inc provides workforce solutions and services, including recruitment and assessment, upskilling, reskilling, training and development, career management, outsourcing, and workforce consulting. The company leverages its trusted brands, industry knowledge, and AI-enabled assessments and offers an extensive portfolio of training and leadership development solutions. Its reportable segments are Staffing and Interim, Outcome-Based Solutions and Consulting, Permanent Recruitment, and Others, with Staffing and Interim generating the majority of revenue. It operates in the Americas, Southern Europe, Northern Europe, and APME. The company derives the maximum geographical revenue from the Southern European region.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.